William Blair starts coverage on Compass Therapeutics, saying its lead drug could reshape bile duct cancer treatment and ...

These inducement grants were approved by Compass Therapeutics Compensation Committee of the Board of Directors as a material inducement to employment. They were granted outside of the Company’s 2020 ...

Compass Inc (NYSE:COMP) is set to release its Q2 2025 earnings on Jul 30, 2025. The consensus estimate for Q2 2025 revenue is $2.08 billion, and the earnings are expected to come in at $0.09 per share ...

We are thrilled to welcome Arjun and Cyndi to the Compass team. They are highly accomplished leaders with decades of commercial and clinical development experience,” said Thomas Schuetz, MD, PhD, CEO ...

An update from Compass ( ($COMP) ) is now available. On September 22, 2025, Compass, Inc. entered into a merger agreement under which its wholly ...

Revenue Grew 23.6% YoY; At High-end of Revenue Guide 851 Gross Principal Agents Joined; An All-time High Operating Cash Flow Grew 102% YoY to $75.5 million Scott Wahlers, Chief Financial Officer of ...

As of July 6, 2023, the average one-year price target for Compass Inc - is 4.15. The forecasts range from a low of 3.54 to a high of $5.25. The average price target represents an increase of 1.79% ...

Compass Therapeutics, Inc. (CMPX) closed the last trading session at $5.39, gaining 13% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

We recently compiled a list of the 10 Best Low Priced Stocks to Invest in Now. In this article, we are going to take a look at where Compass, Inc. (NYSE:COMP) stands against the other low priced ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/compass-inc-reports-record-second-quarter-2025-results-302517839.html ...